3D-QSAR and docking studies on 2-arylbenzoxazole and linker-Y transthyretin amyloidogenesis inhibitors

Science China Chemistry

Volumn 56, Issue 11, 2013, Pages 1550-1563

  Zhao, Lijun ^a   Zhang, Liangren ^b   Lei, Ming ^a  

^a BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

2 arylbenzoxazoles; 3D QSAR; binding mode; docking; linker Y; transthyretin

Indexed keywords

2-ARYLBENZOXAZOLES; 3D-QSAR; BINDING MODES; LINKER-Y; TRANSTHYRETIN;

BINDING ENERGY; DOCKING; ENZYME INHIBITION; MOLECULES; OLIGOMERS; THREE DIMENSIONAL;

COMPUTATIONAL CHEMISTRY;

EID: 84889261968     PISSN: 16747291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11426-013-4894-9     Document Type: Article

References (52)

1. Hamilton JA, Benson MD. Transthyretin: A review from a structural perspective. Cell Mol Life Sci, 2001, 58: 1491-1521
2. Bartalena L, Robbins J. Thyroid hormone transport proteins. Clin Lab Med, 1993, 13: 583-598
3. Schreiber G, Richardson SJ. The evolution of gene expression, structure and function of transthyretin. Comp Biochem Physiol B: Biochem Mol Biol, 1997, 116: 137-160
4. Monaco HL. The transthyretin-retinol-binding protein complex. Biochim Biophys Acta, 2000, 1482: 65-72
5. Palaninathan SK. Nearly 200 X-Ray crystal structures of transthyretin - What do they tell us about this protein and the design of drugs for TTR amyloidoses. Curr Med Chem, 2012, 2324-2342
6. Connors LH, Richardson AM, Theberge R, Costello CE. Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid, 2000, 7: 54-69
7. Takeuchi M, Mizuguchi M, Kouno T, Shinohara Y, Aizawa T, Demura M, Mori Y, Shinoda H, Kawano K. Destabilization of transthyretin by pathogenic mutations in the DE loop. Proteins, 2007, 66: 716-725
8. Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Annu Rev Med, 2000, 51: 543-569
9. Sacchettini JC, Kelly JW. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discovery, 2002, 1: 267-275
10. Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol, 2000, 7: 312-321
11. Lei M, Yang MF, Huo SH. Intrinsic versus mutation dependent instability/flexibility: A comparative analysis of the structure and dynamics of wild-type transthyretin and its pathogenic variants. J Struct Biol, 2004, 148: 153-168
12. Ando Y, Ueda M. Diagnosis and therapeutic approaches to transthyretin amyloidosis. Curr Med Chem, 2012, 19: 2312-2323
13. Wojtczak A, Cody V, Luft JR, Pangborn W. Structures of human transthyretin complexed with thyroxine at 2.0 Å resolution and 3′,5′-dinitro-N-acetyl-L-thyronine at 2.2 Å resolution. Acta Crystallogr D Biol Crystallogr, 1996, 52: 758-765
14. Lauro A, Uso TD, Masetti M, Di Benedetto F, Cautero N, De Ruvo N, Dazzi A, Quintini C, Begliomini B, Siniscalchi A, Ramacciato G, Risaliti A, Miller CM, Pinna AD. Liver transplantation for familial amyloid polyneuropathy non-VAL 30MET variants: Are cardiac complications influenced by prophylactic pacing and immunosuppressive weaning? Transplant Proc, 2005, 37: 2214-2220
15. Hornsten R, Wiklund U, Olofsson BO, Jensen SM, Suhr OB. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation, 2004, 78: 112-116
16. Arsequell G, Planas A. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands. Curr Med Chem, 2012, 19: 2343-2355
17. Nencetti S, Orlandini E. TTR fibril formation inhibitors: Is there a SAR? Curr Med Chem, 2012, 19: 2356-2379
18. Baures PW, Peterson SA, Kelly JW. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem, 1998, 6: 1389-1401
19. Oza VB, Petrassi HM, Purkey HE, Kelly JW. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg Med Chem Lett, 1999, 9: 1-6
20. Oza VB, Smith C, Raman P, Koepf EK, Lashuel HA, Petrassi HM, Chiang KP, Powers ET, Sachettinni J, Kelly JW. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem, 2002, 45: 321-332
21. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem, 2004, 47: 355-374
22. Choi S, Ong DST, Kelly JW. A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate. J Am Chem Soc, 2010, 132: 16043-16051
23. Choi S, Reixach N, Connelly S, Johnson SM, Wilson IA, Kelly JW. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. J Am Chem Soc, 2010, 132: 1359-1370
24. Gupta S, Chhibber M, Sinha S, Surolia A. Design of mechanism-based inhibitors of transthyretin amyloidosis: Studies with biphenyl ethers and new structural templates. J Med Chem, 2007, 50: 5589-5599
25. Petrassi HM, Johnson SM, Purkey HE, Chiang KP, Walkup T, Jiang X, Powers ET, Kelly JW. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: Kinetic stabilization of the native state. J Am Chem Soc, 2005, 127: 6662-6671
26. Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, Arsequell G, Planas A, Saraiva MJ. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J, 2004, 381: 351-356
27. Gales L, Macedo Ribeiro S, Arsequell G, Valencia G, Saraiva MJ, Damas AM. Human transthyretin in complex with iododiflunisal: Structural features associated with a potent amyloid inhibitor. Biochem J, 2005, 388: 615-621
28. Mairal T, Nieto J, Pinto M, Almeida MR, Gales L, Ballesteros A, Barluenga J, Perez JJ, Vazquez JT, Centeno NB, Saraiva MJ, Damas AM, Planas A, Arsequell G, Valencia G. Iodine atoms: A new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. Plos One, 2009, 4: e4124
29. Julius RL, Farha OK, Chiang J, Perry LJ, Hawthorne MF. Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores. Proc Natl Acad Sci USA, 2007, 104: 4808-4813
30. Razavi H, Palaninathan SK, Powers ET, Wiseman RL, Purkey HE, Mohamedmohaideen NN, Deechongkit S, Chiang KP, Dendle MTA, Sacchettini JC, Kelly JW. Benzoxazoles as transthyretin amyloid fibril inhibitors: Synthesis, evaluation, and mechanism of action. Angew Chem Int Edit, 2003, 42: 2758-2761
31. Johnson SM, Petrassi HM, Palaninathan SK, Mohamedmohaideen NN, Purkey HE, Nichols C, Chiang KP, Walkup T, Sacchettini JC, Sharpless KB, Kelly JW. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem, 2005, 48: 1576-1587
32. Johnson SM, Connelly S, Wilson IA, Kelly JW. Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem, 2008, 51: 6348-6358
33. Johnson SM, Connelly S, Wilson IA, Kelly JW. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem, 2008, 51: 260-270
34. Johnson SM, Connelly S, Wilson IA, Kelly JW. Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem, 2009, 52: 1115-1125
35. Wang HF, Tang YH, Lei M. Models for binding cooperativities of inhibitors with transthyretin. Arch Biochem Biophys, 2007, 466: 85-97
36. Yang MF, Lei M, Huo SH. Why is Leu55 -> Pro55 transthyretin variant the most amyloidogenic: Insights from molecular dynamics simulations of transthyretin monomers. Protein Sci, 2003, 12: 1222-1231
37. Yang MF, Lei M, Bruschweiler R, Huo SH. Initial conformational changes of human transthyretin under partially denaturing conditions. Biophys J, 2005, 89: 433-443
38. Yang MF, Yordanov B, Levy Y, Bruschweiler R, Huo SH. The sequence-dependent unfolding pathway plays a critical role in the amyloidogenicity of transthyretin. Biochemistry-US, 2006, 45: 11992-12002
39. Armen RS, Alonso DOV, Daggett V. Anatomy of an amyloidogenic intermediate: Conversion of beta-sheet to alpha-sheet structure in transthyretin at acidic pH. Structure, 2004, 12: 1847-1863
40. Armen RS, DeMarco ML, Alonso DOV, Daggett V. Pauling and Corey's alpha-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease. Proc Natl Acad Sci USA, 2004, 101: 11622-11627
41. Ortore G, Martinelli A. Computational studies on transthyretin. Curr Med Chem, 2012, 19: 2380-2387
42. Wei DG, Yang GF, Wan J, Zhan CG. Binding model construction of antifungal 2-aryl-4-chromanones using CoMFA, CoMSIA, and QSAR analyses. J Agr Food Chem, 2005, 53: 1604-11
43. Yang GF, Huang X. Development of quantitative structure-activity relationships and its application in rational drug design. Current Pharm Design, 2006, 12: 4601-11
44. Chen Q, Zhu XL, Jiang LL, Liu ZM, Yang GF. Synthesis, antifungal activity and CoMFA analysis of novel l,2,4-triazolo-1,5-a pyrimidine derivatives. Europ J Med Chem, 2008, 43: 595-603
45. He Y, Niu C, Li H, Wen X, Xi Z. Experimental and computational correlation and prediction on herbicide resistance for acetohydroxyacid synthase mutants to Bispyribac. Sci China Chem, 2013, 56: 286-95
46. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JA, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Keith T, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Iyengar SS, Tomasi J, Cossi M, Rega N, Millam JM, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas O, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ. Gaussian 09, Revision B.01, Gaussian, Inc., Wallingford CT, 2010.
47. He YZ, Li YX, Zhu XL, Xi Z, Niu C, Wan J, Zhang L, Yang GF. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations. J Chem Inf Model, 2007, 47: 2335-44
48. Zhang L, Cui ZN, Yin B, Yang GF, Ling Y, Yang XL. QSAR and 3D-QSAR studies of the diacyl-hydrazine derivatives containing furan rings based on the density functional theory. Sci China Chem, 2010, 53: 1322-1331
49. Lee SH, Van HT, Yang SH, Lee KT, Kwon Y, Cho WJ. Molecular design, synthesis and docking study of benz[b]oxepines and 12-oxobenzo[c] phenanthridinones as topoisomerase 1 inhibitors. Bioorg Med Chem Lett, 2009, 19: 2444-2447
50. Sun J, Cai S, Yan N, Mei H. Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis. Europ J Med Chem, 2010, 45: 1008-1014
51. Ruppert J, Welch W, Jain AN. Automatic identification and representation of protein binding sites for molecular docking. Protein Sci, 1997, 6: 524-533
52. Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol, 2010, 20: 54-62